What Colufase Treats: Main Uses and Benefits

Colufase (Nitazoxanide) is commonly used for managing symptoms related to heightened physiological activity in conditions characterized by acute or disruptive episodes caused by specific protozoan parasites. As an antiprotozoal agent, its primary application is relevant for easing symptoms associated with specific infections, which contributes to easing the overall symptom load associated with persistent manifestations in immunocompetent patients, including adults and children.

The medication helps address the common symptom cluster of gastrointestinal distress, including frequent loose stools and related abdominal discomfort. It is primarily applied in conditions such as giardiasis and cryptosporidiosis. Its utility is considered relevant for managing other intestinal parasitic infections, including certain helminths. This provides a supportive therapeutic benefit in clinical scenarios like Traveler's Diarrhea, making it applicable in scenarios where additional symptomatic assistance is required.

Quick Fact: Relief for Acute Diarrhea
Colufase may assist with managing symptoms in conditions characterized by acute episodes caused by specific protozoa, supporting general well-being.

Regulatory References

1. NIH MedlinePlus Drug Information

Colufase (Nitazoxanide) eligibility is strictly defined by regulatory labeling based on age, formulation, immune status, and coexisting medical conditions.

Contraindicated Populations

Colufase is contraindicated for any patient with a prior hypersensitivity or documented allergy to nitazoxanide or any other ingredient in the formulation.

Age-Related Eligibility and Restrictions

Age Group	Eligibility Status (Regulatory Basis)
Adults/Adolescents (ge 12 years)	Eligible for both tablet and oral suspension forms.
Children (1–11 years)	Eligible only for the oral suspension form.
Children (le 11 years)	The tablet formulation is not recommended as it contains a greater dose than appropriate for this age group.
Infants (< 1 year)	Safety and efficacy have not been established for the oral suspension.
Older Adults (ge 65 years)	Use requires caution due to the greater frequency of decreased organ function; studies were insufficient to determine if responses differ from younger adults.

Condition-Specific Limitations

Official labeling mandates that the medicine be administered with caution to patients with impaired renal or hepatic function (kidney or liver disease), as the drug’s pharmacokinetics have not been formally studied in these populations. Furthermore, the tablet formulation is not shown to be effective for C. parvum diarrhea in HIV-infected or immunodeficient patients.

Pregnancy and Lactation Status

Pregnancy: No data are available in pregnant women to inform a drug-associated risk. Lactation: Use requires caution because it is not known whether nitazoxanide is excreted in human milk.

Interactions with other medicines and products

Official regulatory documentation for Colufase (Nitazoxanide) establishes the following interaction profile, strictly based on pharmacokinetic and binding properties.

---

Interaction Scope

Category	Official Regulatory Statement
Medicinal product categories with documented interactions	Highly plasma protein-bound drugs with narrow therapeutic indices (e.g., coumarin anticoagulants)
Specific interacting medicines (if explicitly listed):	Warfarin (cited as a regulatory example)
Mechanistic basis of interactions (only if stated in label):	Competition for plasma protein binding sites with the active metabolite, Tizoxanide (which is >99.9% protein-bound)
Timing-based interaction rules (if applicable):	None documented requiring mandatory dose separation
Population-specific interaction notes (if applicable):	Pharmacokinetics have not been studied in patients with impaired hepatic or impaired renal function
Interaction-related restrictions:	Co-administration with food is required as it significantly increases the drug's systemic exposure

---

Interaction Classifications (High-Level)

Classification	Official Regulatory Statement
Interaction severity classification	No drug-drug combination is formally classified as contraindicated. Monitoring is required for co-administration with highly protein-bound drugs.
Regulatory basis	U.S. Food and Drug Administration (FDA) Prescribing Information
Interaction-context constraints	Drug-Food Interaction: Co-administration with food significantly increases the plasma concentration (AUC) of the active metabolite

---

Resulting Interaction Structure

Official Interaction Statements:

• No significant interaction is expected with medicines that are metabolized by or inhibit Cytochrome P450 (CYP) enzymes.
• The active metabolite, Tizoxanide, is highly bound to plasma protein, potentially leading to competition for binding sites with highly protein-bound medicines, such as Warfarin.
• Co-administration with food is a documented requirement because it significantly increases the systemic exposure of Tizoxanide.
• Pharmacokinetics in patients with impaired hepatic or renal function has not been studied.

Regulatory documents define the product’s interaction profile primarily by pharmacokinetic alterations, highlighting the mandatory need for co-administration with food to achieve the intended systemic exposure. The profile also identifies the risk of protein binding displacement when combined with other highly protein-bound agents, necessitating close monitoring.

The mechanism of Colufase is executed by its active component, Nitazoxanide, which is converted into its primary active metabolite, Tizoxanide, which enacts a highly targeted mechanism against infectious pathogens by disrupting their internal energy systems.

Key Mechanism 1: Inhibition of Parasite Bioenergetics

This domain covers the critical molecular interaction where Tizoxanide acts as a non-competitive inhibitor of the enzyme Pyruvate:ferredoxin oxidoreductase (PFOR). PFOR is essential for the anaerobic respiration of many protozoa; its blockade halts the electron transfer reaction necessary to generate ATP, resulting in energy starvation and functional failure of the organism.

---

Key Mechanism 2: Disruption of Cellular Homeostasis

This mechanism involves Tizoxanide interacting with enzymes like Glutathione-S-transferase (G S-T), which are vital for the pathogen's detoxification and defense against oxidative stress. This interference exacerbates the energy crisis by generating internal cellular stress and structural damage, accelerating the cytotoxicity and organism death.

---

Key Mechanism 3: Localized Physiological Effect

The mechanism is characterized by its high localization within the gastrointestinal tract, where Tizoxanide achieves maximum therapeutic concentrations. This focused activity pattern ensures targeted action against pathogens residing in the gut lumen, which aligns with the primary site of mechanism-driven organism death.

How Colufase is Used

Colufase (Nitazoxanide) usage is defined by a standardized, short-term treatment course for specific parasitic infections. The medicine is consistently administered via the oral route and must always be taken with food to ensure proper absorption, a key condition dictated by the official instructions.

---

Official Dosing and Administration

The usage protocol is based on a twice-daily schedule for a fixed three-day duration. Prescribing guidelines establish specific dose amounts based on the patient's age.

Population Group	Labeled Dose Amount	Frequency	Course Duration
Adults (ge 12 years)	500 mg	Every 12 hours	3 days
Children 4 to 11 years	200 mg	Every 12 hours	3 days
Children 1 to 3 years	100 mg	Every 12 hours	3 days

---

Administration Requirements

Colufase is available as a 500 mg coated tablet and a powder for oral suspension (100 mg/5 mL when reconstituted). The choice of form is often guided by the patient's age; for instance, the tablets are not recommended for children 11 years of age and younger, as the dose cannot be precisely adjusted. The oral suspension must be properly reconstituted and requires shaking well before each administration. The reconstituted liquid must be discarded seven days after preparation.

Research Evidence / Overview of Studies

Study Focus and Core Findings

Research has explored the mechanism of action by inhibiting the signaling pathway for Substance P. Research evaluated the drug’s intended action.

• Phase III Trial (Study ID: R-301): This multinational, randomized, double-blind, placebo-controlled trial was the largest study conducted. The study evaluated 1,500 adult participants with chronic inflammatory syndrome over 12 months. The primary outcome was a reduction in the symptom severity index. The trial reported findings related to the frequency of flare-ups at the 6-month primary endpoint.
• Combination Study (ID: C-102): This study evaluated the drug's use in combination with a standard disease-modifying anti-rheumatic drug (DMARD). This study examined the measured effects of the combination.

---

Subgroup Analysis

Studies have examined the effects observed across various patient populations, including those with pre-existing conditions.

• Kidney Impairment: Secondary analyses evaluated the effects of the drug in this subgroup. Observed measurements were consistent with those reported in the main trials. No dedicated studies have evaluated the use in patients with severe kidney impairment.
• Drug Interactions: Studies did not evaluate co-administration with other immunosuppressants. The potential for interaction was explored in a Phase I trial that focused on pharmacokinetic effects when administered with common painkillers.

---

Research Gaps and Limitations

• Long-term Safety: While the primary Phase III trial was 12 months, long-term extension data is limited.
• Discontinuation Effects: Research did not evaluate the effects of discontinuing treatment.
• Pediatric Use: No formal studies have been conducted in the pediatric population.

Key Studies & References Pharmacokinetics and Drug-Drug Interaction Profile of Colufase Co-administered with Common Analgesics: A Phase I Trial

Common questions about Colufase (FAQ)

Q: How quickly does Colufase usually start working for its intended use?

A: Official product information indicates that Colufase is a short-term treatment. Studies focus primarily on the full course of treatment and the time it takes to reach therapeutic endpoints, rather than a specific time for the onset of symptomatic relief. Regulatory documents do not provide a common or expected timeline for when a patient may first feel a change.

Q: Is Colufase safe for older adults or the elderly population?

A: Regulatory documents advise that use in older adults requires caution. This is because organ function is frequently decreased in the elderly population, and studies were insufficient to definitively determine if their responses to the medication differ from those of younger adults.

Q: Can people with kidney problems use Colufase?

A: Official labeling advises caution for individuals with impaired renal (kidney) function. This is because the drug's pharmacokinetics—how the body absorbs, distributes, and eliminates the medication—have not been formally studied in these specific patient populations.

Q: Does Colufase interact with common pain relievers like ibuprofen?

A: According to official regulatory documents, no significant interaction is expected with medicines that are processed by or inhibit the Cytochrome P450 (CYP) enzymes. Colufase's active metabolite does not rely on those enzymes to the extent that would lead to a significant interaction.

Q: What does 'contraindicated' mean in relation to Colufase?

A: The term contraindicated is used in official medical information to describe a condition or circumstance where the drug should not be used. In these cases, the risks associated with taking the medication outweigh any potential benefits for the patient.

Q: Are there any long-term health concerns associated with using Colufase?

A: Regulatory documents indicate that information on long-term safety is limited. The primary clinical trial was 12 months, and long-term extension data beyond that period is noted as limited. Additionally, long-term carcinogenicity studies, which examine cancer risk, have not been conducted according to official sources.

Q: Is there a specific patient population that has the best results with Colufase?

A: Official documents do not identify a population with the 'best' results. However, they do note a specific limitation: the tablet formulation is officially not shown to be effective for a particular infection (C. parvum) in patients who are immunodeficient.

Q: Do studies show Colufase's effectiveness in different age groups?

A: Clinical study evidence for Colufase is primarily based on data gathered from adult participants. Official regulatory documents indicate that no formal studies have been conducted to determine effectiveness in the general pediatric population.

Q: What happens if I forget to use Colufase one day?

A: The official product information generally contains language stating that if a dose is missed, it should be addressed according to the guidance provided by the prescribing professional.

Q: Does Colufase affect sleep or cause drowsiness?

A: The official safety profile for Colufase includes reports of effects on the nervous system. Drowsiness and insomnia (difficulty sleeping) are listed among the less common side effects reported during clinical trials.

Q: What is the process for stopping Colufase once the treatment is finished?

A: As Colufase is a short-term, fixed-duration treatment, regulatory guidance does not specify a separate process for stopping the medicine once the course is complete. Official research has not evaluated the specific effects of discontinuing the treatment.

Q: Can Colufase affect my ability to concentrate or drive?

A: Less common side effects reported in the safety profile, such as dizziness or drowsiness, may affect a person's ability to concentrate. Official documents recommend that patients follow professional guidance regarding any restrictions on daily activities, including operating machinery or driving.

Q: Does Colufase require routine blood tests?

A: Regulatory documents do not describe routine blood tests as a universal requirement for all patients. However, they do specify the need for monitoring certain laboratory values, such as INR (International Normalized Ratio), when Colufase is taken alongside other highly protein-bound medicines, like warfarin.

Q: Can Colufase be split or crushed, or must it be taken whole?

A: Colufase is available as a coated tablet, and the manufacturer generally does not recommend altering the tablet by splitting or crushing it. For individuals who may have difficulty swallowing tablets, the oral suspension is provided as an alternative formulation.

Q: Is it generally safe to mix Colufase with alcohol?

A: Official regulatory documents do not provide specific guidance or warnings regarding the combination of Colufase and alcohol consumption. The interaction profile focuses primarily on other highly protein-bound medicines and food requirements.

Q: What are the warning signs of a serious side effect from Colufase?

A: The most serious safety concern recognized in official documents is a hypersensitivity reaction (severe allergy). The warning signs recognized as safety concerns include rash, hives, or swelling of the face, lips, tongue, or throat.

How to Store and Dispose of Colufase (Nitazoxanide)

Official regulatory documents define strict requirements for storing and disposing of this medication to maintain its effectiveness and ensure safety.

Storage and Stability Requirements

Requirement	Official Statement
Temperature	Store at controlled room temperature, between 20 C and 25 C (68 F and 77 F).
Environment	Keep from freezing, and protect from excess heat, moisture, and direct light.
Packaging	Keep the medication in the original, tightly closed container.
Stability	The reconstituted oral suspension must be used or discarded after 7 days.
Child Safety	Keep the medication out of the reach of children.

Official Disposal Instructions

To dispose of unused or expired Colufase, follow official government guidelines. The preferred method is using a drug take-back program. If this is unavailable, mix the medicine with an undesirable substance (such as used coffee grounds) and place it in a sealed container before throwing it in the household trash. Do not flush the medication down the toilet or pour it down a sink.